MURANO, a randomized phase III study sponsored by Abbvie, showed that patients with relapsed or refractory chronic lymphocytic leukemia achieved significantly prolonged median progression-free survival with Venclexta/Venclyxto (venetoclax) in combination with Rituxan (rituximab) [median PFS, not reached], compared with bendamustine in combination with Rituxan [median PFS, 17.0 months; hazard ratio, 0.17; 95% CI, 0.11–0.25; P<0.0001].
The phase III frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi/Minjuvi), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma or high-grade B-cell lymphoma, has produced positive results.
